US Department of Defense selects Pharm-Olam as CRO for Adalimumab COVID Therapeutic Trial

Pharm-Olam has been selected by the U.S. Department of Defense to lead and provide full service clinical trial support of the Adalimumab COVID Therapeutic Trial.